An observational real world study to evaluate the malignancy risk in rheumatoid arthritis patients treated with Abatacept and that of Biologic Disease-modifying Antirheumatic Drug (bDMARD)

Trial Profile

An observational real world study to evaluate the malignancy risk in rheumatoid arthritis patients treated with Abatacept and that of Biologic Disease-modifying Antirheumatic Drug (bDMARD)

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Jul 2017

At a glance

  • Drugs Abatacept (Primary) ; Adalimumab; Anakinra; Certolizumab pegol; Etanercept; Golimumab; Infliximab; Rituximab; Tocilizumab
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Most Recent Events

    • 02 Jul 2017 New trial record
    • 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top